{
    "info": {
        "nct_id": "NCT06414889",
        "official_title": "Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants with RUNX1 Familial Platelet Disorder",
        "inclusion_criteria": "Participants who meet all of the following criteria are eligible to be included in the study:\n\n1. Are aged ≥ 18 to 75 years\n\n   a. Once a favorable review of safety has been completed by the SMC in 3 participants aged ≥ 18 years, the study will be opened to participants aged ≥ 12 years.\n2. Are willing and able to provide informed consent, as appropriate (either directly or through a legally authorized representative [LAR]), as described in Appendix 1, Section 13.1\n3. Have a confirmed diagnosis of RUNX1 FPD, verified by a Clinical Laboratory Improvement Amendments (CLIA)-certified genetic sequencing report.\n4. Clearance by apheresis team to proceed\n5. Have systolic blood pressure ≤ 170 mm Hg and diastolic blood pressure ≤ 95 mmHg\n6. Are eligible for HSCT per institution requirements\n7. Have a Lansky (age < 16 years)/Karnofsky performance status of ≥ 70 (see Appendix 2, Section 13.2).\n8. Are willing and able to comply with protocol-defined contraceptive requirements (see Appendix 3 Section 13.3)\n9. Have a platelet count ≥ 50,000/μL for initiation of apheresis, assessed within 24 hours prior to the procedure, or, if < 50,000/μL are administered platelets on the day of the collection\n\n   a. If the apheresis team decides that a central venous catheter (CVC) is to be placed, platelet count should be ≥ 50,000 prior to catheter placement.\n10. Have hemoglobin ≥ 7.5 g/dL as assessed within 24 hours prior to the procedure\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 75 Years",
        "exclusion_criteria": "Participants who meet any of the following criteria are excluded from the study:\n\n1. Participants with cognitive impairments and/or any serious unstable pre-existing medical condition or psychiatric disorder that can interfere with safety or with obtaining informed consent or compliance with study procedures.\n2. Have uncontrolled bleeding\n3. Are using supplemental oxygen\n4. Have known severe splenomegaly (≥ 20 cm)\n5. Have a diagnosis of MDS or hematologic malignancies, as defined by WHO hematolymphoid tumor classification fifth edition (Khourey et al 2022) hematolymphoid tumor classification fifth edition (Khourey et al 2022)\n6. Have recent prior malignancies except resected basal cell carcinoma or treated cervical carcinoma in situ Note: Cancer treated with curative intent < 5 years previously may be allowed following approval from the study investigator. Cancer treated with curative intent > 5 years previously is allowed.\n7. Have any prior or current myeloproliferative or a significant coagulation or immunodeficiency disorder\n8. Have advanced liver disease, defined as any of the following:\n\n   1. Persistent aspartate transaminase, alanine transaminase, or direct bilirubin value > 5× the upper limit of normal (ULN) at screening\n   2. Screening prothrombin time (PT) or partial thromboplastin time (PTT) > 1.5× ULN\n9. Have had prior HSCT or gene therapy\n10. Have history of concomitant sickle cell disease\n11. Have been treated with an investigational drug within 30 days of screening or 5 half-lives (whichever is longer)\n12. Have a positive test result for HIV, hepatitis B virus (HBV), or hepatitis C virus (HCV) at screening\n\n    1. Participants with positive hepatitis B core antibody (HbcAb) and/or hepatitis B-e antibody (HbeAb) are eligible provided viral load is negative by quantitative polymerase chain reaction (qPCR).\n    2. Participants who are positive for anti-hepatitis C antibody are eligible as long as they have a negative HCV viral load by qPCR.\n13. Have a positive infectious disease panel at screening for human T-lymphotropic virus 1 or 2 (HTLV-1 and HTLV-2), or syphilis (rapid plasma 24 reagin [RPR])\n14. Have clinically significant and active bacterial, viral, fungal, or parasitic infection at screening\n15. Have a white blood cell (WBC) count < 2 × 109/L\n16. Have a left ventricular ejection fraction < 45%\n17. Have a screening estimated glomerular filtration rate < 60 mL/min/1.73 m2\n18. Have a diagnosis of a significant psychiatric disorder that could seriously impede the ability to participate in the study\n19. For women of childbearing potential: are pregnant or breastfeeding or lack adequate contraception\n20. Are unable to comply with the study procedures, as assessed by the investigator",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "3. Have a confirmed diagnosis of RUNX1 FPD, verified by a Clinical Laboratory Improvement Amendments (CLIA)-certified genetic sequencing report.",
            "criterions": [
                {
                    "exact_snippets": "confirmed diagnosis of RUNX1 FPD",
                    "criterion": "RUNX1 FPD diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "verified by a Clinical Laboratory Improvement Amendments (CLIA)-certified genetic sequencing report",
                    "criterion": "genetic sequencing report certification",
                    "requirements": [
                        {
                            "requirement_type": "certification",
                            "expected_value": "CLIA-certified"
                        },
                        {
                            "requirement_type": "report_type",
                            "expected_value": "genetic sequencing"
                        }
                    ]
                }
            ]
        },
        {
            "line": "a. If the apheresis team decides that a central venous catheter (CVC) is to be placed, platelet count should be ≥ 50,000 prior to catheter placement.",
            "criterions": [
                {
                    "exact_snippets": "If the apheresis team decides that a central venous catheter (CVC) is to be placed, platelet count should be ≥ 50,000 prior to catheter placement.",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50000,
                                "unit": ""
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have maximum age of 75 Years",
            "criterions": [
                {
                    "exact_snippets": "maximum age of 75 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 75,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Are willing and able to comply with protocol-defined contraceptive requirements (see Appendix 3 Section 13.3)",
            "criterions": [
                {
                    "exact_snippets": "willing and able to comply with protocol-defined contraceptive requirements",
                    "criterion": "compliance with contraceptive requirements",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Have a Lansky (age < 16 years)/Karnofsky performance status of ≥ 70 (see Appendix 2, Section 13.2).",
            "criterions": [
                {
                    "exact_snippets": "Lansky (age < 16 years) ... performance status of ≥ 70",
                    "criterion": "Lansky performance status",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": "<",
                                "value": 16,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 70,
                                "unit": ""
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Karnofsky performance status of ≥ 70",
                    "criterion": "Karnofsky performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 70,
                                "unit": ""
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Are willing and able to provide informed consent, as appropriate (either directly or through a legally authorized representative [LAR]), as described in Appendix 1, Section 13.1",
            "criterions": [
                {
                    "exact_snippets": "willing and able to provide informed consent, as appropriate (either directly or through a legally authorized representative [LAR])",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "method of consent",
                            "expected_value": [
                                "directly",
                                "through a legally authorized representative (LAR)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Are eligible for HSCT per institution requirements",
            "criterions": [
                {
                    "exact_snippets": "Are eligible for HSCT per institution requirements",
                    "criterion": "HSCT eligibility",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "per institution requirements",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Clearance by apheresis team to proceed",
            "criterions": [
                {
                    "exact_snippets": "Clearance by apheresis team to proceed",
                    "criterion": "apheresis team clearance",
                    "requirements": [
                        {
                            "requirement_type": "clearance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "a. Once a favorable review of safety has been completed by the SMC in 3 participants aged ≥ 18 years, the study will be opened to participants aged ≥ 12 years.",
            "criterions": [
                {
                    "exact_snippets": "participants aged ≥ 18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "participants aged ≥ 12 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Have hemoglobin ≥ 7.5 g/dL as assessed within 24 hours prior to the procedure",
            "criterions": [
                {
                    "exact_snippets": "hemoglobin ≥ 7.5 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7.5,
                                "unit": "g/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "as assessed within 24 hours prior to the procedure",
                    "criterion": "hemoglobin assessment timing",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 24 hours prior to the procedure"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Are aged ≥ 18 to 75 years",
            "criterions": [
                {
                    "exact_snippets": "aged ≥ 18 to 75 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 18,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 75,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Have a platelet count ≥ 50,000/μL for initiation of apheresis, assessed within 24 hours prior to the procedure, or, if < 50,000/μL are administered platelets on the day of the collection",
            "criterions": [
                {
                    "exact_snippets": "platelet count ≥ 50,000/μL for initiation of apheresis",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50000,
                                "unit": "/μL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "assessed within 24 hours prior to the procedure",
                    "criterion": "platelet count assessment timing",
                    "requirements": [
                        {
                            "requirement_type": "time window",
                            "expected_value": "within 24 hours prior to the procedure"
                        }
                    ]
                },
                {
                    "exact_snippets": "if < 50,000/μL are administered platelets on the day of the collection",
                    "criterion": "platelet count and platelet administration",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 50000,
                                "unit": "/μL"
                            }
                        },
                        {
                            "requirement_type": "platelet administration",
                            "expected_value": "on the day of the collection"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Have systolic blood pressure ≤ 170 mm Hg and diastolic blood pressure ≤ 95 mmHg",
            "criterions": [
                {
                    "exact_snippets": "systolic blood pressure ≤ 170 mm Hg",
                    "criterion": "systolic blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 170,
                                "unit": "mm Hg"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "diastolic blood pressure ≤ 95 mmHg",
                    "criterion": "diastolic blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 95,
                                "unit": "mmHg"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "1. Persistent aspartate transaminase, alanine transaminase, or direct bilirubin value > 5× the upper limit of normal (ULN) at screening",
            "criterions": [
                {
                    "exact_snippets": "Persistent aspartate transaminase ... value > 5× the upper limit of normal (ULN) at screening",
                    "criterion": "aspartate transaminase",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Persistent ... alanine transaminase ... value > 5× the upper limit of normal (ULN) at screening",
                    "criterion": "alanine transaminase",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Persistent ... direct bilirubin value > 5× the upper limit of normal (ULN) at screening",
                    "criterion": "direct bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 5,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "16. Have a left ventricular ejection fraction < 45%",
            "criterions": [
                {
                    "exact_snippets": "left ventricular ejection fraction < 45%",
                    "criterion": "left ventricular ejection fraction",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 45,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Have history of concomitant sickle cell disease",
            "criterions": [
                {
                    "exact_snippets": "history of concomitant sickle cell disease",
                    "criterion": "sickle cell disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "concomitant",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Have advanced liver disease, defined as any of the following:",
            "criterions": [
                {
                    "exact_snippets": "advanced liver disease",
                    "criterion": "advanced liver disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Screening prothrombin time (PT) or partial thromboplastin time (PTT) > 1.5× ULN",
            "criterions": [
                {
                    "exact_snippets": "Screening prothrombin time (PT) ... > 1.5× ULN",
                    "criterion": "prothrombin time (PT)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "partial thromboplastin time (PTT) > 1.5× ULN",
                    "criterion": "partial thromboplastin time (PTT)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Participants who are positive for anti-hepatitis C antibody are eligible as long as they have a negative HCV viral load by qPCR.",
            "criterions": [
                {
                    "exact_snippets": "positive for anti-hepatitis C antibody",
                    "criterion": "anti-hepatitis C antibody",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "negative HCV viral load by qPCR",
                    "criterion": "HCV viral load by qPCR",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Have a positive infectious disease panel at screening for human T-lymphotropic virus 1 or 2 (HTLV-1 and HTLV-2), or syphilis (rapid plasma 24 reagin [RPR])",
            "criterions": [
                {
                    "exact_snippets": "positive infectious disease panel at screening for human T-lymphotropic virus 1 or 2 (HTLV-1 and HTLV-2)",
                    "criterion": "HTLV-1 infection",
                    "requirements": [
                        {
                            "requirement_type": "infectious disease panel result",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "positive infectious disease panel at screening for human T-lymphotropic virus 1 or 2 (HTLV-1 and HTLV-2)",
                    "criterion": "HTLV-2 infection",
                    "requirements": [
                        {
                            "requirement_type": "infectious disease panel result",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "positive infectious disease panel at screening for ... syphilis (rapid plasma 24 reagin [RPR])",
                    "criterion": "syphilis infection (RPR)",
                    "requirements": [
                        {
                            "requirement_type": "infectious disease panel result",
                            "expected_value": "positive"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Participants with positive hepatitis B core antibody (HbcAb) and/or hepatitis B-e antibody (HbeAb) are eligible provided viral load is negative by quantitative polymerase chain reaction (qPCR).",
            "criterions": [
                {
                    "exact_snippets": "positive hepatitis B core antibody (HbcAb)",
                    "criterion": "hepatitis B core antibody (HbcAb)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "positive ... hepatitis B-e antibody (HbeAb)",
                    "criterion": "hepatitis B-e antibody (HbeAb)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "provided viral load is negative by quantitative polymerase chain reaction (qPCR)",
                    "criterion": "hepatitis B viral load (by qPCR)",
                    "requirements": [
                        {
                            "requirement_type": "viral load",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "18. Have a diagnosis of a significant psychiatric disorder that could seriously impede the ability to participate in the study",
            "criterions": [
                {
                    "exact_snippets": "diagnosis of a significant psychiatric disorder",
                    "criterion": "psychiatric disorder",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    ]
                },
                {
                    "exact_snippets": "could seriously impede the ability to participate in the study",
                    "criterion": "ability to participate in the study",
                    "requirements": [
                        {
                            "requirement_type": "impediment",
                            "expected_value": "seriously impeded"
                        }
                    ]
                }
            ]
        },
        {
            "line": "20. Are unable to comply with the study procedures, as assessed by the investigator",
            "criterions": [
                {
                    "exact_snippets": "Are unable to comply with the study procedures, as assessed by the investigator",
                    "criterion": "ability to comply with study procedures",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment by investigator",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Have any prior or current myeloproliferative or a significant coagulation or immunodeficiency disorder",
            "criterions": [
                {
                    "exact_snippets": "prior or current myeloproliferative ... disorder",
                    "criterion": "myeloproliferative disorder",
                    "requirements": [
                        {
                            "requirement_type": "history or presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "significant coagulation ... disorder",
                    "criterion": "coagulation disorder",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    ]
                },
                {
                    "exact_snippets": "significant ... immunodeficiency disorder",
                    "criterion": "immunodeficiency disorder",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Are using supplemental oxygen",
            "criterions": [
                {
                    "exact_snippets": "Are using supplemental oxygen",
                    "criterion": "supplemental oxygen use",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "19. For women of childbearing potential: are pregnant or breastfeeding or lack adequate contraception",
            "criterions": [
                {
                    "exact_snippets": "are pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "lack adequate contraception",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Have recent prior malignancies except resected basal cell carcinoma or treated cervical carcinoma in situ Note: Cancer treated with curative intent < 5 years previously may be allowed following approval from the study investigator. Cancer treated with curative intent > 5 years previously is allowed.",
            "criterions": [
                {
                    "exact_snippets": "Have recent prior malignancies except resected basal cell carcinoma or treated cervical carcinoma in situ",
                    "criterion": "recent prior malignancies",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": [
                                "resected basal cell carcinoma",
                                "treated cervical carcinoma in situ"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Cancer treated with curative intent < 5 years previously may be allowed following approval from the study investigator",
                    "criterion": "cancer treated with curative intent < 5 years previously",
                    "requirements": [
                        {
                            "requirement_type": "allowance",
                            "expected_value": "may be allowed following approval from the study investigator"
                        }
                    ]
                },
                {
                    "exact_snippets": "Cancer treated with curative intent > 5 years previously is allowed",
                    "criterion": "cancer treated with curative intent > 5 years previously",
                    "requirements": [
                        {
                            "requirement_type": "allowance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Have known severe splenomegaly (≥ 20 cm)",
            "criterions": [
                {
                    "exact_snippets": "Have known severe splenomegaly (≥ 20 cm)",
                    "criterion": "splenomegaly",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">=",
                                "value": 20,
                                "unit": "cm"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Have a diagnosis of MDS or hematologic malignancies, as defined by WHO hematolymphoid tumor classification fifth edition (Khourey et al 2022) hematolymphoid tumor classification fifth edition (Khourey et al 2022)",
            "criterions": [
                {
                    "exact_snippets": "Have a diagnosis of MDS or hematologic malignancies, as defined by WHO hematolymphoid tumor classification fifth edition (Khourey et al 2022)",
                    "criterion": "diagnosis of MDS or hematologic malignancies",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "definition standard",
                            "expected_value": "WHO hematolymphoid tumor classification fifth edition (Khourey et al 2022)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Have uncontrolled bleeding",
            "criterions": [
                {
                    "exact_snippets": "uncontrolled bleeding",
                    "criterion": "bleeding",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Have a positive test result for HIV, hepatitis B virus (HBV), or hepatitis C virus (HCV) at screening",
            "criterions": [
                {
                    "exact_snippets": "positive test result for HIV ... at screening",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "positive test result for ... hepatitis B virus (HBV) ... at screening",
                    "criterion": "hepatitis B virus infection",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "positive test result for ... hepatitis C virus (HCV) at screening",
                    "criterion": "hepatitis C virus infection",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Participants with cognitive impairments and/or any serious unstable pre-existing medical condition or psychiatric disorder that can interfere with safety or with obtaining informed consent or compliance with study procedures.",
            "criterions": [
                {
                    "exact_snippets": "cognitive impairments",
                    "criterion": "cognitive impairment",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "serious unstable pre-existing medical condition",
                    "criterion": "serious unstable pre-existing medical condition",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "psychiatric disorder that can interfere with safety or with obtaining informed consent or compliance with study procedures",
                    "criterion": "psychiatric disorder interfering with safety, informed consent, or compliance",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "interference with safety or with obtaining informed consent or compliance with study procedures",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "17. Have a screening estimated glomerular filtration rate < 60 mL/min/1.73 m2",
            "criterions": [
                {
                    "exact_snippets": "screening estimated glomerular filtration rate < 60 mL/min/1.73 m2",
                    "criterion": "estimated glomerular filtration rate (eGFR)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 60,
                                "unit": "mL/min/1.73 m2"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Have been treated with an investigational drug within 30 days of screening or 5 half-lives (whichever is longer)",
            "criterions": [
                {
                    "exact_snippets": "Have been treated with an investigational drug within 30 days of screening or 5 half-lives (whichever is longer)",
                    "criterion": "treatment with investigational drug",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 30,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "Participants who meet all of the following criteria are eligible to be included in the study:",
            "criterions": []
        }
    ],
    "failed_exclusion": [
        {
            "line": "15. Have a white blood cell (WBC) count < 2 × 109/L",
            "criterions": [
                {
                    "exact_snippets": "white blood cell (WBC) count < 2 × 10^9/L",
                    "criterion": "white blood cell count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2,
                                "unit": "× 10^9/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Participants who meet any of the following criteria are excluded from the study:",
            "criterions": []
        },
        {
            "line": "14. Have clinically significant and active bacterial, viral, fungal, or parasitic infection at screening",
            "criterions": [
                {
                    "exact_snippets": "clinically significant and active bacterial ... infection at screening",
                    "criterion": "bacterial infection",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "presence at screening",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "clinically significant and active viral ... infection at screening",
                    "criterion": "viral infection",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "presence at screening",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "clinically significant and active fungal ... infection at screening",
                    "criterion": "fungal infection",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "presence at screening",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "clinically significant and active ... parasitic infection at screening",
                    "criterion": "parasitic infection",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "presence at screening",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Have had prior HSCT or gene therapy",
            "criterions": [
                {
                    "exact_snippets": "Have had prior HSCT",
                    "criterion": "prior HSCT",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "have had ... gene therapy",
                    "criterion": "prior gene therapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}